Wednesday, July 8, 2026

Patent intelligence · US

US 9636305

Antiemetic extended release solid dosage forms

granted A61KA61K31/4178A61K9/2013A61K9/2054
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 11
Applicant portfolio 40
Patent details — US 9636305
Jurisdiction
US
Status
granted
Grant date
May 2, 2017
Expiration
Apr 27, 2037
Claims
10
CPC classes
A61K, A61K31/4178, A61K9/2013, A61K9/2054
View on Google Patents ↗

Quick answer

US 9636305 (Antiemetic extended release solid dosage forms) is held by RedHill Biopharma Ltd.. Status: granted. Granted May 2, 2017. Expires Apr 27, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
10
CPC classes
A61K, A61K31/4178, A61K9/2013, A61K9/2054, A61K9/209, A61K9/2846

More from RedHill Biopharma Ltd.

Related pharmaceutical patents in our USPTO index.

  1. US 12370206

    Therapy for inhibition of single-stranded RNA virus replication

    RedHill Biopharma Ltd. · Expires Jul 24, 2045

    granted
  2. US 12115150

    Biomarkers of coronavirus pneumonia

    RedHill Biopharma Ltd. · Expires Oct 10, 2044

    granted
  3. US 11931463

    All-in-one fixed-dose combination for treating Helicobacter pylori infection

    RedHill Biopharma Ltd. · Expires Mar 14, 2044

    granted
  4. US 11918560

    Serine protease inhibitor for treating coronavirus infection

    RedHill Biopharma Ltd. · Expires Feb 29, 2044

    granted
  5. US 11878011

    Method for eradicating Helicobacter pylori infection in patients regardless of body mass index

    RedHill Biopharma Ltd. · Expires Jan 18, 2044

    granted
  6. US 11786541

    Inhibitor of sphingosine kinase 2 for treating Ebola

    RedHill Biopharma Ltd. · Expires Oct 12, 2043

    granted
  7. US 11633385

    Combination compositions for treatment of cancer

    RedHill Biopharma Ltd. · Expires Apr 20, 2043

    granted
  8. US 11590154

    Triple antibiotic fixed-dose combination products, dosing regimen, methods, and kits for treating pulmonary non-tuberculosis mycobacterial infections

    RedHill Biopharma Ltd. · Expires Feb 23, 2043

    granted

Frequently asked questions

What is US patent 9636305?

US 9636305 (Antiemetic extended release solid dosage forms) is held by RedHill Biopharma Ltd.. Status: granted. Granted May 2, 2017. Expires Apr 27, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9636305?

RedHill Biopharma Ltd. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 40 pharmaceutical patents for this assignee.

When does US 9636305 expire?

Our index shows an expiration date of Apr 27, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.